Fetal growth restriction (FGR) can reflect a clinical situation where the placenta is working poorly, leading to a fetus that is suboptimally grown. Importantly, FGR is strongly associated with stillbirth risk. It is therefore an important clinical surrogate marker of stillbirth. Identification of mRNA coding six genes are differentially expressed in the blood of mothers as early as 28 weeks, who are destined to develop FGR at term. For such pregnancies, the clinicians could offer timely delivery and thereby decrease the burden of stillbirth.